CIK 0001868279 · Non-accelerated filer<br>Emerging growth company
ArriVent BioPharma, Inc.
Sign in to watch- Ticker
- AVBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 240-780-6356
- Business address
- 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise | +16,265 | $3.65 | $59K | 152,001 |
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise | +410 | $2.28 | $935 | 152,411 |
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise | +4,550 | $2.28 | $10K | 156,961 |
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise | +1,820 | $2.28 | $4K | 158,781 |
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise | +17,648 | $6.24 | $110K | 176,429 |
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −410 | 0 | ||
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −4,550 | 1,820 | ||
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −1,820 | 0 | ||
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −16,265 | 2,600 | ||
| 2026-10-30 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −17,648 | 38,823 | ||
| 2026-06-18 | Parsey Merdad Director | Grant or award · Non-Qualified Stock Option (right to buy) | +13,562 | 13,562 | ||
| 2026-06-18 | Peterson Kristine Director | Grant or award · Non-Qualified Stock Option (right to buy) | +13,562 | 13,562 | ||
| 2026-06-18 | Hohneker John Director | Grant or award · Non-Qualified Stock Option (right to buy) | +13,562 | 13,562 | ||
| 2026-06-18 | Nolet Chris Director | Grant or award · Non-Qualified Stock Option (right to buy) | +13,562 | 13,562 | ||
| 2026-02-02 | LaChapelle Robin Chief Operating Officer | Grant or award · Stock Option (right to buy) | +130,000 | 130,000 | ||
| 2026-02-02 | Lutzker Stuart President of R&D | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2026-02-02 | Kung Winston Chief Financial Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2026-02-02 | Yao Zhengbin President and CEO | Grant or award · Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2026-02-02 | Kastenmayer James Paul General Counsel | Grant or award · Stock Option (right to buy) | +130,000 | 130,000 | ||
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10% owner | Sale | −555,555 | $23.37 | $13.0M | 3,929,117 |
Page 1 of 4 · 78 trades